Table 1. Mean Reciprocal Neutralizing Titers of Post-H5n1 Human Sera.
| SAMPLE | VIETNAM | TURKEY | ANHUI | INDONESIA |
| (CLADE 1) | (CLADE 2.2) | (CLADE 2.3.4) | (CLADE 2.1) | |
| 90 µg H5N1 Vaccine | ||||
| 1 | 40 | <20 | 20 | <20 |
| 2 | 40 | 20 | 40 | <20 |
| 3 | <20 | <20 | <20 | <20 |
| 4 | 20 | <20 | <20 | <20 |
| 120 µg H5N1 Vaccine | ||||
| 1 | 40 | 20 | 40 | <20 |
| 2 | 40 | <20 | 20 | <20 |
| 3 | 80 | 20 | 40 | <20 |
| 4 | 20 | <20 | 20 | <20 |
| 180 µg H5N1 Vaccine | ||||
| 1 | 40 | <20 | 20 | <20 |
| 2 | 80 | 20 | 40 | <20 |
| 3 | 80 | 40 | 40 | 20 |
| 4 | 40 | 20 | 20 | <20 |
*End-point titers (mean of three replicates) using human sera after two vaccinations with inactivated H5N1 vaccine in a microneutralization assay performed with performed with rgH5N1 x PR8.